Identification of the IgG binding site of the human low affinity receptor for IgG FcγRII. Enhancement and ablation of binding by site-directed mutagenesis

M. D. Hulett, E. Witort, R. I. Brinkworth, I. F.C. McKenzie, P. M. Hogarth

Research output: Contribution to journalArticleResearchpeer-review

64 Citations (Scopus)


Fc receptor-antibody interactions are key mechanisms through which antibody effector functions are mediated. The low affinity receptor for IgG, FcγRII, is expressed on most hematopoietic cells, and through the binding of immune complexes mediates a large spectrum of biological responses vital for resistance to infection and the regulation of immunity. In this study the key residues of human FcγRII involved in the interaction with IgG1 have been identified. Chimeric receptors composed of extracellular regions of FcγRII and the FcεRI α chain have been used to localize the IgG1 binding site of FcγRII to an 8-residue stretch in the second extracellular domain, Asn154 to Ser161. Site-directed mutagenesis of this region revealed that substitution of Ile155 or Gly156 with alanine ablated the binding of human and mouse IgG1, whereas replacement of Leu159, Phe160, or Ser161 with alanine enhanced binding. Molecular modeling has been used to generate a putative 3-dimensional model structure of the second extracellular domain of FcγRII, suggesting that the binding site lies in an exposed loop region at the interface of domains 1 and 2.

Original languageEnglish
Pages (from-to)15287-15293
Number of pages7
JournalJournal of Biological Chemistry
Issue number21
Publication statusPublished - 1 Jan 1994
Externally publishedYes

Cite this